FIELD : medicine.SUBSTANCE : group of inventions relates to medicine, specifically to oncology, and can be used to treat early stage cancer with overexpression/amplification of HER-2/neu. To this end, after completing one year of adjuvant therapy with trastuzumab, the patient is administered neratinib. Neratinib is administered to the patient for a period of twelve months at a daily dose of 240?mg. Neratinib administration begins more than 2 weeks and less than four years after the last dose of trastuzumab. Method of increasing the survival of a patient without signs of disease, and a method of treatment for increasing survival without signs of invasive disease are also disclosed.EFFECT : group of inventions provides treatment of early stage cancer with overexpression/amplification of HER-2/neu in a patient.16 cl, 1 ex